Lancet 365: 1046–1053 Obstructive sleep apnea-hypopnea is widely considered to be a cardiovascular risk factor, but there are few prospective data to confirm this link or to establish whether ...

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

Background: The pathogenesis of daytime hypercapnia (PaCO 2 ≥ 45 mm Hg) may be directly linked to the existence of obstructive sleep apnea ... index (BMI) and apnea-hypopnea index (AHI) values ...

However, the machines tend to be ... May 30, 2024 — A new study demonstrates that when individuals with obstructive sleep apnea use their positive airway pressure machine more regularly ...

In two Eli Lilly trials spanning 52 weeks, nondiabetic patients with obstructive sleep apnea experienced a clinically meaningful reduction in events of apnea, stops in breathing, or hypopnea ...

Would you please address the dangers of untreated sleep apnea? Also, what do people do when they are unable to tolerate a ...

The first medication for obstructive sleep apnea has been approved by ... and clinically meaningful reduction in events of apnea or hypopnea," and a large share of participants achieved remission ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Sleep apnea affects millions of people worldwide and prevents them from getting quality sleep. It negatively affects patients ...

Would you please address the dangers of untreated sleep apnea? Also, what do people do when they are unable to tolerate a CPAP (continuous positive airway pressure) ...

The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, ...

The first medication for obstructive sleep apnea has been approved by ... and clinically meaningful reduction in events of apnea or hypopnea,” and a large share of participants achieved ...